Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

Background: To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC). Patients and methods: Twenty-one patients with untreated, metastatic, EGFR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2006-03, Vol.17 (3), p.450-456
Hauptverfasser:	Folprecht, G., Lutz, M. P., Schöffski, P., Seufferlein, T., Nolting, A., Pollert, P., Köhne, C.-H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cetuximab chemotherapy Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Disease Progression ErbB Receptors - metabolism Fluorouracil - administration & dosage Gastroenterology. Liver. Pancreas. Abdomen Humans Irinotecan Leucovorin - administration & dosage Medical sciences metastatic colorectal cancer Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!